MERILOG

Sanofi partnered with Brandsymbol to develop a name for the first FDA-approved rapid-acting insulin biosimilar for diabetes treatment. As a biosimilar to Novo Nordisk’s NovoLog, the name needed to balance differentiation while clearly communicating its equivalence to the reference product.


Leveraging our experience from naming Admelog (the biosimilar to Humalog), we understood the importance of the “Log” suffix—an industry-standard naming convention for rapid-acting insulins derived from “analog insulin.” Maintaining this familiar structure helps ensure provider and patient confidence while reinforcing interchangeability. The “Meri” prefix was chosen to evoke merit, quality, and reliability, positioning MERILOG as a trusted, effective, and affordable option for diabetes patients.


By applying our i4 Methodology, we strategically crafted a name that fits seamlessly into the insulin market while carving out a distinct identity. MERILOG’s approval represents a milestone in diabetes care, introducing a new category of affordable treatment options through biosimilars and expanding access for patients who rely on rapid-acting insulin.


For more information, visit Sanofi or read the FDA approval announcement.